Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study

BACKGROUND: Sorafenib is a multiple receptor tyrosine kinase inhibitor known to prolong overall survival in patients with advanced hepatocellular carcinoma (HCC). Predicting this drug’s survival benefits is challenging because clinical responses are rarely measurable during treatment. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Tomoyuki, Yamashita, Taro, Terashima, Takeshi, Suda, Tsuyoshi, Okada, Hikari, Asahina, Yoshiro, Hayashi, Takehiro, Hara, Yasumasa, Nio, Kouki, Sunagozaka, Hajime, Takatori, Hajime, Arai, Kuniaki, Sakai, Yoshio, Yamashita, Tatsuya, Mizukoshi, Eishiro, Honda, Masao, Kaneko, Shuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738185/
https://www.ncbi.nlm.nih.gov/pubmed/29258450
http://dx.doi.org/10.1186/s12885-017-3889-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738185/
https://www.ncbi.nlm.nih.gov/pubmed/29258450
http://dx.doi.org/10.1186/s12885-017-3889-x

Ejemplares similares